T1	Participants 56 111	patients affected by acne and polycystic ovary syndrome
T2	Participants 506 566	women with acne and proven PCOS therapy with estroprogestins
T3	Participants 886 961	women affected by mild to severe acne and polycystic ovary syndrome (PCOS).
T4	Participants 970 1064	Fifty-nine women were randomized to receive EE/DRSP (n = 32) or EE/CMA (n = 27) for six months
